PROs in Anticancer Trials Should Focus on Five Core Areas, FDA Guidance Says
July 30, 2021
An FDA draft guidance released June 9 provides sponsors of anticancer therapies with a list of five core areas that patient-reported outcomes (PRO) measures should focus on to demonstrate a therapy’s effect on survival, tumor response or disease progression.